Preliminary Report on Residual Lung Damage in Long COVID-19 Using AD-cSVF In Clinical Trial NCT# 04326036

Robert W Alexander*
Northwest Institute of Cellular and Biocellular Research USA

*Corresponding author: Robert W Alexander, Northwest Institute of Cellular and Biocellular Research, USA.


Copyright© 2023 by Alexander RW. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Clinical Trial of Treatment Long COVID-19 Patient Residual Damage

- Overview Summary of Understanding & Management
- Explain Clinical Trial of Use Of cSVF In Long COVID Lung
- Brief Description of cSVF Use In COPD/FLD Patients
- Fluidda Analysis of COVID Lungs (Functional Pulmonary Images) For Diagnosis, Prediction, Management & Outcome Tracking
- Brief Introduction Followed By COVID Background & Beliefs

Understanding COVID-19

- Overview Summary of Understanding & Management
- Explain Clinical Trial Of Use Of cSVF In Long COVID Lung
- Brief Description of cSVF Use In COPD/FLD Patients
- Fluidda Analysis Of COVID Lungs (Functional Pulmonary Images) For Diagnosis, Prediction, Management & Outcome Tracking
Brief Introduction Followed By COVID Background & Beliefs

Early Beliefs On COVID-19

- Thought Likely Aerosol and Contact Spread
- Was Uncertain If Man-To-Man Spread (Quickly Dispelled)
- Thought Lungs Were Primary Target Impacted (Is Primary Entry)
- Some Presented ARDS Symptoms (But NOT Respond The Same)
- Presented With Generalized Viral Flu-Like Symptoms/Cough
- High Temps, Dropping O2 Saturations (even on O2), Patient Not Always Aware Sats Falling Below 90
- Mostly Older Patients, Pre-Existing Illnesses, Nursing Homes
- EVOLVED UNDERSTANDING COVID-19
  - Immune System Failure, Often Severe Atypical ARDS (ICU, Vent)
  - Sudden Loss Lung Respiratory Functional Capacity ***
  - Later Stage Huge Immune/Inflammatory Reaction (Cytokine)
  - ARDS Progression NOT Following Classic Pulmonary Viral Infections
  - Clots-MicroThrombi (Lungs, Heart, Brain, Kidney, Extremities, Liver)
  - DIC Noted EVEN In Patients With No Co-Morbidities
  - Known Attack Point at ACE2 Cell Wall Receptors (Lungs, Blood Vessel Linings, Kidneys, Intestines, etc.)
- Oxidative Stresses Are Elevated Within COVID-19 Process (ROS)

Progressive Alveolar Damage In COVID-19
Mechanisms Of Lung & Peripheral Clotting In Covid-19

- Damage Occurs In Endothelial Walls Vessels – Many ACE2 Receptors Yielding High Angiotensin II Levels – Same Target as COVID Lung
- Spike Protein Of Virus Targets the ACE2 Receptors (Lungs, Capillary Endothelial Cells & Lung Alveolar Type II Cells, etc.)
- Elevated vWF Levels (Subendothelial) + Factor 8 in Circulation = Clotting
- Increased D-Dimer Levels, Lowered Platelet Levels (Reflects Clotting)
- Patients Display Serious Oxidative Stress & Thrombus Symptoms
- Impaired Gas Diffusion (Vascular Inequality - V/Q Ratio Changes)

Early Management Tried in Covid-19 Ars

- Ventilator Tidal Volumes Were Often Set TOO HIGH
- Often Tried Excessive PEEP Pressures (Both Did Not Raise O2 Sat)
- Tried Supine Vs. Prone Positioning Which Helped (Ref: Guerin – NEJM)
- Failure If Induced Coma Levels Not Enough (Vent Override Issue)
- Caused Over-Distention Lungs + Fluid Leaks into Alveoli (Lower Ventilation/Perfusion Resulted With The “Cytokine Storm” Damage)
- Resulted in Infiltration Fibroblasts, Scarring & Alveolar Loss

Common Case Management in Covid-19

- Ventilatory Support Escalation:
- Medium & High Flow O2
- CPAP/BPAP and Select Use Of PEEP
- Intubation & Full Ventilator Monitored TV (Long Term Need Is Common)
- Induced Coma To Permit Ventilatory Support
- Longer Prone Positioning Scheduling (Improves Ventilation)
- Used Steroids, AntiOxidants, AntiCoagulants, Variety of Medications
- NOTE:  Often Resulted in Permanent Lung Air Exchange Damage

Clinical Trial Background Using CsVF

- Proposal For Phase 0/I Based On Experiences With cSVF in COPD & Fibrotic Lung Disorders (FLD) in Clinical Trials
- Two Years Of Existing Trials + For Safety and Efficacy In Progress
- FLUIDDA Analytics Available For Functional Respiratory Imaging
- Major Value In Diagnostics, Prognostications, Management
- Study Examines Lung Damage Changes Achieved with cSVF + Other Systemic Findings Common In Long-COVID (>12 Week, Persistent)
- Prognostication Value Permits Early Interventions Needed
- COPD/FLD Group Showing Clinical Improvement In Function

Background & Logic Of cSVF Use

DOI: https://doi.org/10.52793/JSCR.2023.4(2)-52
• Studied Homeostasis & Wound Healing
• Examined How We Remodel, Repair & Maintain
• Learning More Stem + Stromal Cells & Their Possible Roles
• Known Importance For Repair/Regen In ALL Tissues
• Site Specific Changes: Microenvironment & Paracrine Functions Appear of Major Importance
• Concentrates Contribute Cells & Signal Proteins (Including Exosomes/MV) To React At Needed Sites
• Has Produced An Excellent Safety Profile In Autologous Use cSVF

Understanding Adult Stem Cells
• Wikipedia: “Adult Stem Cells are multipotent, undifferentiated cells found throughout the body after development, that multiply via Asymmetric Cell Division to replenish dying cells and regenerate damaged tissues”.
• Adult stem cells values center on ability to divide & self-renew indefinitely, either generating the SAME cell or other cell types than the tissue from which they originate! (Basis for Multipotency)

Study NCT #04326036
• Harvesting, Isolation/Concentration cSVF (Digestion) – IV Deploy
• FUNCTIONAL RESPIRATORY IMAGING (FRI) – Fluidda Analysis
• Uses HRCT-LUNG (Low Radiation Dose, Thin CT (<1mm), Taken At Functional Full Inhalation/Exhalation) -- Not A Std CT Lung
• Baseline and 6-12 Month Samples For Comparative Analytics
• Baseline and 6 Month Sample Std. PFA For Comparative Analytics
• Monitoring O2 Sats, Supplemental O2 Changes, DOE, etc.

Cellular SVF Use In COPD/FLD
• Known Ability To Mitigate Inflammatory Reactions
• Known Mitigation Immune Responses (Immunomodulatory Effects)
• Autologous, Heterogeneous Cellular, Paracrine, & Signaling Effects
• Elements Includes Innate & Adaptive Immune Response Cell Types
• Non-Designated Cells (MSC, Perivascular Group) + Paracrine Effects
• Known to “Home” To Damaged-Inflamed Areas
• Signaling Via Exosomes/MV Secretions From Key Reparative Cells & Native Local Damaged Area Cells (Cell-To-Cell Communication)

Accessing/Concentrating AD-SVF Components
• Disposable, Sterile Microcannula With Tulip GEMS (2.11 mm)
• Usual Compressed Volume (After Centrifugation) 20-25 cc ATC
• Enzymatic Isolation/Incubation/Concentration Of AD-cSVF (Stem/Stromal Cell Elements)
• Neutralization/Rinsing Of cSVF (Removal Residual Enzyme)
• Resuspension In Normal Saline (Buffered) and Deployment

DOI: https://doi.org/10.52793/JSCR.2023.4(2)-52
• Arbitrary Target Minimum Number Of 100 Million SVF Cells To Deploy IV Trial And Verified Flow Cytometry For Numbers, Cell Integrity (Viability Measure), Cell Size Averaging

Disposable Microcannula System

 FluiddAnalytics:
 Functional Respiratory Imaging (Fri)
 • Been VERY Valuable In Analysis of cSVF in COPD/FLD & COVID-19
 • High Resolution CT LUNGS (Functional Exam NOT Chest CT)
 • Relatively Low Dose Radiation; Rapid, Thin Section Of Full Inspiration/Expiration
 • Proven Value In Diagnostics, Prediction, Tracking Management
 • Shows Significant Air Perfusion/Exchange Changes
 • Uses CT Lung (at Both TLC and FRC) For Airways & Vascular
 • Useful Both In Active & Post-Infection Populations

Example Covid-19 Hrct Images

Covid-19 Moderate Damage

Covid-19 Severe Damage (Scarring)
Vascular Patterns in Lung Diseases

Trial Patient #7: Vascular Changes

Ventilation/Perfusion Changes With cSVF

Example: Actual Exam Baseline-6 Months

Trial Patient #8 – Perfusion Impact

DOI: https://doi.org/10.52793/JSCR.2023.4(2)-52
Fluidda Analysis: Frc (Actual Copd Patient)

Trial Patient #8: Fluidda Analysis

Trial Patient #1: Fluidda Analysis

DOI: https://doi.org/10.52793/JSCR.2023.4(2)-52
Acknowledgment
Thanks To Black Tie Medical for Sponsoring Clinical Trial. Appreciation of Efforts of Pat Alexander, Nancy Smith & Susan Riley For Their Very Important Contributions To Carry Out This Trial